The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...
The FDA approved Johnson & Johnson’s Spravato nasal spray as a stand-alone treatment for patients suffering from severe ...
Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...
The FDA has approved Spravato (esketamine) nasal spray for use as monotherapy for patients with treatment-resistant depression.
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
The FDA has approved esketamine (Spravato) nasal spray as a monotherapy for adults with treatment-resistant depression. This ...
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...
The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...
One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...